Insomnia – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Insomnia is the most common clinical condition in which the person experiences difficulty sleeping and is subclassified as short-term, chronic, and other. Sometimes it is described as the presence of polysomnographic evidence of disturbed sleep. Therefore insomnia is considered to exist when there is long sleep latency, frequent nocturnal awakening, prolonged wakefulness throughout the sleep phase, or transient arousals. Insomnia can be a primary sleep disorder, comorbid sleep condition, and other mental or medical disorders. The etiology includes environmental, genetic, behavioral, and physiological factors culminating in hyperarousal. Insomnia is the complex interaction between cognitive arousal, altered circulation, and the homeostatic system. Decreased function of the sleep-walk switch may also contribute to insomnia. During sleep, there is a gradual shift from non-rapid-eye movement (non-REM) sleep to rapid-eye-movement (REM) sleep. The most common symptom was trouble sustaining sleep(61%), followed by early morning awakening(2.2%), difficulties beginning sleep(7.7%), and nonrestorative sleep (7.7%). The American Academy of Sleep Medicine divides rest into five stages: Stage W (wakefulness), Stage N1 (relaxed wakefulness), Stage N2 (light sleep), Stage N3 (deep or slow-wave sleep), and Stage R (REM sleep or dreaming). N1-N3 are non-REM sleep stages with minimal cortical activity, whereas REM sleep has significant cortical activity.

 

In the U.S., approximately 30% to 40% of adults have insomnia. Short-term insomnia has an estimated prevalence of 9.5%, and 1 in 5 cases of short-term insomnia progresses to chronic insomnia. People with poor health or impaired quality of life are more likely to suffer from insomnia (QOL).

 

The competitive landscape of Insomnia includes country-specific approved and pipeline therapies. Any asset/product-specific designation, review, and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Insomnia across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Insomnia Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake, and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Insomnia – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          Zolpidem           Biolab Sanus Farmaceutica       Phase 3

2          CBT-I plus Melatonin     Ache Laboratorios Farmaceuticos S.A.            Phase 3

3          Lemborexant     Eisai Inc.          Phase 3

4          SM-1    Sequential Medicine Ltd Phase 3

5          Daridorexant     Idorsia Pharmaceuticals Ltd.      Phase 2

6          Neu-P11           Neurim Pharmaceuticals Ltd.     Phase 2

7          Tasimelteon      Vanda Pharmaceuticals Phase 3

8          Esmirtazapine   Merck Sharp & Dohme LLC       Phase 3

9          MMFS-205-SR  Neurocentria, Inc.          Phase 2

10        Cannabidiol       Defined Research          Phase 2

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more